“Precision medicine is personalised and creating individualised treatments for a whole range of conditions, so how is it changing the way we manage disease? Philip Clark spoke to John Mattick a Professor of RNA Biology at UNSW and Professor Robert Green is the Director of the Genomes2People Research Program at Harvard Medical School.”
“Amy McGuire [Co-PI of BabySeq] joins Laura Hercher on “The Beagle Has Landed” to discuss BabySeq and the high-risk, high-reward prospect of making genome sequencing of newborns routine. After a preliminary study many years in the making, Amy is here to assure us of one thing: ‘what we’re doing isn’t Gattaca.’ Also, the take-home message: … Continued
“We have a wild card here that is changing the risk-benefit equation for all babies in order to detect these rare cases.”
“If you go to a scientific meeting, even with the greatest critics, and you ask, how many people in this audience believe that your entire genome will be part of your everyday medical care in fifty years, every person will raise their hand. So the only questions we’re debating are: how do we get there, … Continued
“We might think that science and money have nothing to do with each other, but whether it’s video games, consumer DNA kits, or even the concrete we build with, the connections are everywhere. Listen to Dr. Mitu Khandaker, Dr. John Orr, and Dr. Jason Vassy explore what happens when research and commercial interests collide.”
Dr. Robert C. Green joins Patrick Short of “The Genetics Podcast” to discuss genetic testing in healthy adults and newborns, along with the barriers we need to overcome to realize the full potential of personalized medicine.
In this season finale of the Latest Med News Podcast, G2P’s Bethany Zettler shares about her work as lead genetic counselor of the Preventive Genomics Clinic and project manager of the MilSeq and BabySeq studies. Her work focuses on how genetic testing can help anyone understand their health risks and make proactive medical/lifestyle choices.
Greg and Robert explode some of the persistent myths around genetic testing and dive in to the future of genetic testing amongst healthy populations
What would happen if everyone got their genome sequenced? This question is no longer the stuff of science fiction. Instead, it is a research question that Senior Genetic Counselor Carrie Blout and her colleagues at the Genomes2People initiative at Brigham and Women’s hospital are trying to answer. We discuss the medical, psychological, and economic impact … Continued
Harry Glorikian guest this week, Dr. Robert Green, is a professor of medicine and genetics at Harvard Medical School and director of the Genomes To People research program at Brigham & Women’s Hospital and the Broad Institute of Harvard and MIT. They dig into the individual genome, how genomic data is being used, and the impact … Continued
Mike Richman of VA Research Communications interviews Dr. Jason Vassy, a clinician and researcher at the VA Boston Healthcare System. Vassy is leading a study that is focusing on whether a test for a specific gene can help patients and doctors choose the right type and dose of statin drugs, which are often used by … Continued
Growing up in a small town in Illinois, musician Pete Wentz didn’t look or feel like others in his community, and never really felt that he fit in. So, he set out to create an identity of his own. On the latest episode of Spit, host Baratunde Thurston sits with Pete and medical geneticist and … Continued
The third and final interview conducted with Dr. Robert Green about specific circumstances that could arise from genetic sequencing starting from infancy.
“The promises and peril that could come from reading your full genome.” Dr. Robert Green discusses some very important questions about what information you could find in your genome.
Robert C. Green sits down with Rob Reid to discuss the advantages and disadvantages of looking into your own genome.
Much of genetic mutation classification is still to be determined by researchers, but what they do know can potentially help many patients with hypertrophic cardiomyopathy in this specific study.
